Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Concerning the Monthly Exercise Status of the 70th and 71st Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clauses)

In October 2026, 2,830,000 new shares were delivered through the exercise of the 70th Stock Acquisition Rights. The unexercised Stock Acquisition Rights at month-end totaled 408,700.

Worth reading
60In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2830000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Report on the monthly exercise status of Stock Acquisition Rights with an exercise price adjustment clause issued through a third-party allotment

Who receives how much

Shares delivered during the subject month: 2,830,000 shares (2,830,000 new shares and 0 treasury shares transferred)

EVO FUND (allottee of the 70th and 71st Stock Acquisition Rights)

The lower thin line represents the existing number of shares to which these shares will be added.

Existing Shares and Increase
+3.30%Rate of increase
84,548,960 shares87,378,960Shares

Shares delivered during the subject month: 2,830,000; issued shares outstanding at the end of the month preceding the subject month: 84,548,960 (approximately 3.3% on a simple calculation)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price during the subject month: ¥46–¥56. A share price-linked adjustment clause applies. The adjustment floor was Not disclosed
Number of Stock Acquisition Rights
Total issued 70th Stock Acquisition Rights: 480,000; exercised during the subject month: 28,300; unexercised at the end of the subject month: 408,700
Basis for determining the amount to be paid
The exercise price was adjusted daily during October, within a range of ¥46 to ¥56. The calculation basis and discount rate were Not disclosed
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise limits under Article 434 of the Listing Regulations. The number of shares delivered across all series was 2,830,000, and the exercise ratio under the exercise limits was 3.5%.
Most recent equity financing
Issued on 2 September 2026: the 70th and 71st Stock Acquisition Rights (with exercise price adjustment clauses). Amount: Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReport on the monthly exercise status of Stock Acquisition Rights with an exercise price adjustment clause issued through a third-party allotment
Number of shares to be issued or disposed ofShares delivered during the subject month: 2,830,000 shares (2,830,000 new shares and 0 treasury shares transferred)
Intended allotteeEVO FUND (allottee of the 70th and 71st Stock Acquisition Rights)
Dilution RateShares delivered during the subject month: 2,830,000; issued shares outstanding at the end of the month preceding the subject month: 84,548,960 (approximately 3.3% on a simple calculation)
Total number of issued shares84,548,960 shares (as of the end of the month preceding the subject month) → 87,378,960 shares (calculated by adding the shares delivered during the subject month)
Basis for determining the amount to be paidThe exercise price was adjusted daily during October, within a range of ¥46 to ¥56. The calculation basis and discount rate were Not disclosed
Exercise priceExercise price during the subject month: ¥46–¥56. A share price-linked adjustment clause applies. The adjustment floor was Not disclosed
Number of Stock Acquisition RightsTotal issued 70th Stock Acquisition Rights: 480,000; exercised during the subject month: 28,300; unexercised at the end of the subject month: 408,700
Procedures under the Corporate Code of ConductDescribes compliance with the exercise limits under Article 434 of the Listing Regulations. The number of shares delivered across all series was 2,830,000, and the exercise ratio under the exercise limits was 3.5%.
Most recent equity financingIssued on 2 September 2026: the 70th and 71st Stock Acquisition Rights (with exercise price adjustment clauses). Amount: Not disclosed
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status. Exercise of the 71st Stock Acquisition Rights is structured to be unavailable until the Company instructs the holder to begin exercising, so disclosure of the monthly exercise status has been omitted.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of the 70th and 71st Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clauses) | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori